BA
ONCT

Ballew Advisors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Ballew Advisors’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4
Closed -$1K – 469
2018
Q3 		$1K Buy
+4
New +$9.6K ﹤0.01% 470

Other funds holding ONCT

BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ballew Advisors's ONCT Position: Q4 2018 in Review

Ballew Advisors sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2018, closing a stake of 4 shares — an estimated $1K sold.

Ballew Advisors first reported a position in ONCT in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 43 funds tracked by Wall St. Rank hold ONCT as of Q4 2018.

  • Ballew Advisors reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Ballew Advisors sold 4 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $1K.
  • Ballew Advisors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • Ballew Advisors's Oncternal Therapeutics, Inc. Common Stock position peaked at $1K in Q3 2018.
  • 43 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Ballew Advisors's 13F filing for Q4 2018, filed 12 Feb 2019.